Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9609264 | 0.74 | LMNA (0.37) | LMNACYP3A4ALOX15GAAHSD17B10 | |
| SCHEMBL9609262 | 0.73 | LMNA (0.36) | LMNACYP3A4ALOX15GAAHSD17B10 | |
| SCHEMBL14037713 | 0.72 | GAA (0.39) | LMNACYP3A4ALOX15GAAHSD17B10 | |
| SCHEMBL9433422 | 0.68 | CYP2C19 (0.40) | LMNACYP2C19HSD17B10 | |
| SCHEMBL15472985 | 0.67 | EPHX1 (0.40) | LMNACYP3A4ALOX15GAA | |
| SCHEMBL25840121 | 0.66 | GAA (0.33) | GAA | |
| SCHEMBL1773678 | 0.65 | GAA (0.34) | LMNACYP3A4ALOX15GAA | |
| SCHEMBL11965894 | 0.65 | TSHR (0.39) | HSD17B10 | |
| SCHEMBL16807393 | 0.64 | ALDH1A1 (0.36) | — | |
| SCHEMBL3846321 | 0.64 | GAA (0.33) | GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2474535-B1 | SYNTHETIC METHOD OF MONTELUKAST SODIUM INTERMEDIATE | SHANDONG NEW TIME PHARMACEUTICAL CO LTD (CN) | 2014-07-02 | — | — | EP | disclosed |
| US-8569508-B2 | Synthetic method for montelukast sodium intermediate | SHANDONG NEW TIME PHARMACEUTICAL CO., LTD. (CN) | 2013-10-29 | — | — | US | disclosed |
| EP-2474535-A1 | SYNTHETIC METHOD OF MONTELUKAST SODIUM INTERMEDIATE | Shandong New Time Pharmaceutical Co., Ltd. (CN) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165535-A1 | SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE | SHANDONG NEW TIME PHARMACEUTICAL CO. LTD. (CN) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165535-A1 | SYNTHETIC METHOD FOR MONTELUKAST SODIUM INTERMEDIATE | LTC4S, CMA1, PTGIS | LMNA 2098/4885CYP3A4 268/4885ALOX15 2010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.